Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Strategies to manage renal AA amyloidosis and advances in this space

Peter Kvacskay • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Anakinra Antibodies Canakinumab Tocilizumab

In this video, Peter Kvacskay, MD, Heidelberg University Hospital, Heidelberg, Germany, shares some insights into strategies used to manage patients with renal AA amyloidosis, including interleukin-1 blocking agents such as anakinra and canakinumab, and renal transplantation. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Peter Kvacskay

3:46
Unmet needs in patients with AA amyloidosis with renal involvement
Peter Kvacskay • 6 Sep 2022
1:03
The efficacy of tocilizumab in patients with advanced renal AA amyloidosis
Peter Kvacskay • 6 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals